Table 2.

Baseline disease characteristics in 155 mantle cell lymphoma patients

Prognostic factorN = 155
Time since initial diagnosis to first dose (y)
    Mean (SD)2.7 (1.9)
    Median2.3
    Minimum, maximum0.2, 11.2
Diagnosed <3 y before first dose, n (%)103 (66)
Diagnosed ≥3 y before first dose, n (%)52 (34)
MCL stage at screening, n (%)/n (%)
    Stage I/II5 (3)/7 (5)
    Stage III/IV24 (15)/119 (77)
IPI score
    0-134 (23)
    248 (33)
    348 (33)
    4-517 (12)
    Missing8
LDH, n (%)/n (%)
    Normal/elevated95 (64)/54 (36)
    Missing6
No. involved extranodal sites, n (%)/n (%)
    0/138 (25)/64 (41)
    2/≥332 (21)/21 (14)
Bone marrow evaluation (biopsy and/or aspirate)
    Positive results84 (55)
    Negative/indeterminate70 (45)
No. prior lines of therapy
    1/284 (54)/ 65 (42)
    ≥36 (4)
Received prior regimen containing the following agents
    Anthracycline/mitoxantrone152 (98)
    Alkylating agents150 (97)
    Rituximab149 (96)
Received at least 2 of the above 3155 (100)
Received all of the above 3141 (91)
Received prior high-intensity therapy*58 (37)
Received prior high-intensity therapy as last prior regimen*47 (30)
  • Abbreviations: MCL, mantle cell lymphoma; IPI, International Prognostic Index; LDH, lactate dehydrogenase.

  • * High-intensity prior regimen defined as hyper-CVAD, R-hyper-CVAD, ICE/ESHAP/DHAP with or without rituximab, and stem cell transplant.